Paroxetine and pindolol

Tome, Maria; Isaac, Michael T.; Harte, Rosarii; Holland, Carlijn

doi:10.1097/00004850-199703000-00003

Cited by 150 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…has been used in most depression studies, yet PET imaging studies suggest that this dose is likely suboptimal for an adequate occupancy of 5-HT 1A receptor [49]. This agent has generated a lot of interest because it has been shown to accelerate antidepressant response when combined with SSRIs in most [50,51,52,53,54,55], but not all [56] studies. In some studies, higher response rates were reported at endpoint with pindolol augmentation than with placebo augmentation [50, 52, 55, 57, 58].…”

Section: Augmentation Studiesmentioning

confidence: 99%

Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice

Fava

Rush

2006

Psychother Psychosom

138

View full text Add to dashboard Cite

Most patients with major depressive disorder (MDD) do not reach symptom remission. These patients with residual symptoms have worse function and worse prognosis than those who remit. Several augmentation and combination treatments are used to either increase the chances of achieving remission or to eliminate/minimize residual depressive symptoms. Evidence for these pharmacological approaches rests primarily on open, uncontrolled studies, and there are clearly not enough controlled studies. Clinicians should carefully weigh these different treatment options to increase their patients’ chances of achieving and sustaining remission from depression. This paper will review the pertinent studies and will propose a novel approach to improve practice involving the use of augmentation or combination strategies at the outset of initial treatment to primarily enhance the chances of remission through synergy and/or a broader spectrum of action. This novel approach could potentially enhance retention and/or increase remission rates since the lack of response with antidepressant monotherapy may lead many depressed patients with little or no benefit to drop out of treatment, precluding the subsequent use of augmentation or combination strategies altogether. In addition, the emergence of certain side-effects (e.g., agitation, insomnia) or the persistence of some initial baseline symptoms (e.g., anxiety, insomnia) may lead to premature discontinuation from monotherapy in the absence of concomitant use of augmenting pharmacological options targeting these symptoms.

show abstract

Section: Augmentation Studiesmentioning

confidence: 99%

Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice

Fava

Rush

2006

Psychother Psychosom

138

View full text Add to dashboard Cite

show abstract

“…In light of the potential utility in anxiety and cognitive disorders of 5-HT 3 receptor ligands, it would be of interest, the development of compounds with affinity of both 5-HT 1A and 5-HT 3 receptors subtypes. In fact antagonist of 5-HT 3 serotonin receptor subtype which is only ligand-gated cation channel receptor [151] are of special interest not only because of their wide clinical use as antiemetic drug in cancer patients [152,153] but also due to their promising therapeutic potential in the treatment of CNS disorders [154,155] Co administration of a 5-HT 1A antagonist and a SSRI has been shown to accelerate antidepressant effect [161,162]. This dual pharmacological profile should lead, in principle, to a rapid and pronounced enhancement in serotoninergic neurotransmission and consequently to a more efficacious treatment of depression.…”

Section: Arylpiperazines With Mixed Receptors Profilementioning

confidence: 99%

Derivatives as 5HT1A Receptor Ligands-Past and Present

Caliendo¹,

Santagada²,

Perissutti³

et al. 2005

CMC

View full text Add to dashboard Cite

Serotonin is a neuromediator, well-know for its implication in mood regulation, anxiety, depression and, insomnia as well as in normal human function such as sleep, sexual activity and appetite. In this way, serotonin (5-hydroxytryptamine, 5-HT) is one of the most attractive targets for medicinal chemists and pharmaceutical companies. Among 5-HTRs, the 5-HT1A subtype is the best studied, and it is generally accepted that it is involved in psychiatric disorders such as anxiety and depression. Several structurally different compounds are known to bind 5-HT1A receptor sites such as aminotetralins, ergolines, arylpiperazines, indolylalkylamines, aporphines and aryloxyalkyl-amines. In this review, we report an overview of the 5-HT1A receptor ligands, belonging to different chemical classes.

show abstract

“…It is possible that the contradictory results from these studies could be due to differences in the way the SSRI was augmented, the study population, the study design, and the pindolol dose [ 22 ]. Howeer, the majority of positive pindolol augmentation studies were conducted with either fluoxetine [ 23 , 24 , 25 , 26 ] or paroxetine [ 27 , 28 , 29 , 30 ] because both these SSRIs increase plasma levels of pindolol, supporting the earlier finding that higher levels of pindolol may be more effective [ 13 ].…”

Section: Selective Partial Agonist and Reuptake Inhibitor (Spari)—vil...mentioning

confidence: 70%

Recent Developments in Pharmacotherapy of Depression: Bench to Bedside

Shad

2023

JPM

View full text Add to dashboard Cite

For the last 70 years, we did not move beyond the monoamine hypothesis of depression until the approval of the S-enantiomer of ketamine, an N-methyl-D-aspartate (NMDA) receptor blocker and the first non-monoaminergic antidepressant characterized by rapid antidepressant and antisuicidal effects. A similar profile has been reported with another NMDA receptor antagonist, dextromethorphan, which has also been approved to manage depression in combination with bupropion. More recently, the approval of a positive allosteric modulator of GABA-A receptors, brexanolone, has added to the list of recent breakthroughs with the relatively rapid onset of antidepressant efficacy. However, multiple factors have compromised the clinical utility of these exciting discoveries in the general population, including high drug acquisition costs, mandatory monitoring requirements, parenteral drug administration, lack of insurance coverage, indirect COVID-19 effects on healthcare systems, and training gaps in psychopharmacology. This narrative review aims to analyze the clinical pharmacology of recently approved antidepressants and discuss potential barriers to the bench-to-bedside transfer of knowledge and clinical application of exciting recent discoveries. Overall, clinically meaningful advances in the treatment of depression have not reached a large proportion of depressed patients, including those with treatment-resistant depression, who might benefit the most from the novel antidepressants.

show abstract

Paroxetine and pindolol

Cited by 150 publications

References 0 publications

Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice

Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice

Derivatives as 5HT1A Receptor Ligands-Past and Present

Recent Developments in Pharmacotherapy of Depression: Bench to Bedside

Contact Info

Product

Resources

About